.png)
HB8734 declares it the Sense of Congress that FDA approval of medication abortion preempts state laws requiring in-person dispensing or restricting telehealth prescribing; the American Council urges its defeat.
OUR POSITIONHB8734 was introduced on May 11, 2026, and referred to the House Committee on Energy and Commerce. Though framed as a non-binding Sense of Congress declaration, the bill makes sweeping assertions that carry real political and legal weight. The American Council opposes this bill and urges every reader to contact their representative and ask that it be defeated.
The bill declares that medication abortion is an extremely safe medical treatment appropriately approved by the FDA, and that this approval preempts any state law requiring in-person dispensing by a health care practitioner. It further asserts that FDA approval preempts any state prohibition or restriction on prescribing or dispensing medication abortion by means of telehealth. These are not neutral descriptive statements. They are policy positions embedded in a congressional record, and the American Council believes they are the wrong positions for Congress to enshrine.
We recognize that the bill contains no operative legal mandate, no appropriation, and no direct amendment to existing statute. But we do not regard this as a reason to dismiss its importance. Sense of Congress language shapes how courts, agencies, and future legislators read federal intent. A declaration that federal approval categorically nullifies state-level in-person dispensing requirements and telehealth restrictions is a significant assertion about the limits of state authority over medical practice, and it deserves to be weighed and, in our view, rejected on its merits.
The American Council holds that communities and their elected state representatives retain a legitimate and constitutionally grounded role in setting standards for how medications are dispensed and how medical care is delivered within their borders. Declaring by congressional resolution that this role is simply preempted by a federal approval decision cuts against that principle. We believe this is a step in the wrong direction, regardless of the non-binding form it takes.
We urge constituents to act now. Call your representative, write a letter, and make clear that you want HB8734 defeated. The bill is in committee, and that is precisely when constituent voices carry the most influence. Do not wait.
HB8734 was introduced in the House on May 11, 2026, and referred the same day to the House Committee on Energy and Commerce, where it currently sits without a scheduled hearing. The bill carries only one chamber referral and no companion Senate bill has been identified from the information available, which suggests it has not yet built the cross-chamber infrastructure that would accelerate its path. Because the bill is at the earliest stage of the committee process, constituent contact directed at members of the Energy and Commerce Committee and at representatives generally is most consequential right now, before any markup or hearing is scheduled.